Literature DB >> 14519676

Development of a microdilution method to evaluate Mycobacterium tuberculosis drug susceptibility.

Elena Banfi1, Giuditta Scialino, Carlo Monti-Bragadin.   

Abstract

A new rapid microdilution method, employing the dye resazurin as an indicator of mycobacterial growth, was developed to evaluate drug susceptibility of Mycobacterium tuberculosis reference strain H37Rv and of 13 M. tuberculosis susceptible or multidrug-resistant clinical strains. Different growth conditions were evaluated. The MICs of isoniazid, rifampicin, streptomycin and ethambutol were determined by the Microdilution Resazurin Assay (MRA) and the results compared with those obtained by the agar proportion method; complete agreement was always obtained. MRA resulted in a rapid, reliable, simple and inexpensive coloured method suitable for testing the susceptibility of M. tuberculosis clinical strains to first-line drugs; its employment in evaluating new antibacterial molecules is also suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519676     DOI: 10.1093/jac/dkg439

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Susceptibilities of Mycobacterium tuberculosis to isoniazid and rifampin on blood agar.

Authors:  Ahmet Yilmaz Coban; Kemal Bilgin; Meltem Uzun; Nuriye Tasdelen Fisgin; Alper Akgunes; Cigdem Cekic Cihan; Asuman Birinci; Belma Durupinar
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds.

Authors:  Mattia Zampieri; Balazs Szappanos; Maria Virginia Buchieri; Andrej Trauner; Ilaria Piazza; Paola Picotti; Sébastien Gagneux; Sonia Borrell; Brigitte Gicquel; Joel Lelievre; Balazs Papp; Uwe Sauer
Journal:  Sci Transl Med       Date:  2018-02-21       Impact factor: 17.956

3.  Experimental Confirmation that an Uncommon rrs Gene Mutation (g878a) of Mycobacterium tuberculosis Confers Resistance to Streptomycin.

Authors:  Pilar Domenech; Esma Mouhoub; Michael B Reed
Journal:  Antimicrob Agents Chemother       Date:  2022-01-24       Impact factor: 5.938

4.  Phenotypic and genomic comparison of Mycobacterium aurum and surrogate model species to Mycobacterium tuberculosis: implications for drug discovery.

Authors:  Amine Namouchi; Mena Cimino; Sandrine Favre-Rochex; Patricia Charles; Brigitte Gicquel
Journal:  BMC Genomics       Date:  2017-07-13       Impact factor: 3.969

5.  General Toxicity and Antifungal Activity of a New Dental Gel with Essential Oil from Abies Sibirica L.

Authors:  Aurelija Noreikaitė; Rizvangul Ayupova; Elmira Satbayeva; Aida Seitaliyeva; Marzhan Amirkulova; Guram Pichkhadze; Ubaidilla Datkhayev; Edgaras Stankevičius
Journal:  Med Sci Monit       Date:  2017-01-29

6.  Hemisynthesis and Biological Evaluation of Cinnamylated, Benzylated, and Prenylated Dihydrochalcones from a Common Bio-Sourced Precursor.

Authors:  Anne Ardaillou; Jérôme Alsarraf; Jean Legault; François Simard; André Pichette
Journal:  Antibiotics (Basel)       Date:  2021-05-22

7.  Phytochemical analysis and antibacterial evaluation of the ethyl acetate extract of the stem bark of Bridelia micrantha.

Authors:  Anthonio O Adefuye; Roland N Ndip
Journal:  Pharmacogn Mag       Date:  2013-01       Impact factor: 1.085

8.  Lanostane- and cycloartane-type triterpenoids from Abies balsamea oleoresin.

Authors:  Serge Lavoie; Charles Gauthier; Jean Legault; Sylvain Mercier; Vakhtang Mshvildadze; André Pichette
Journal:  Beilstein J Org Chem       Date:  2013-07-04       Impact factor: 2.883

9.  Anti tuberculosis drug resistance in west of iran.

Authors:  Parviz Mohajeri; Baharak Norozi; Sara Atashi; Abbas Farahani
Journal:  J Glob Infect Dis       Date:  2014-07

10.  Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families.

Authors:  George W Kasule; David P Kateete; Moses L Joloba
Journal:  BMC Infect Dis       Date:  2016-04-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.